These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2425926)

  • 1. Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.
    Okuno K; Takagi H; Nakamura T; Nakamura Y; Iwasa Z; Yasutomi M
    Cancer; 1986 Sep; 58(5):1001-6. PubMed ID: 2425926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.
    Ishikawa T; Imawari M; Moriyama T; Ohnishi S; Matsuhashi N; Suzuki G; Takaku F
    J Cancer Res Clin Oncol; 1988; 114(3):283-90. PubMed ID: 2838488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma.
    Fagan EA; Pulley M; Limb A; Wolstencroft R; Cranenburgh C; De Vinci C; Karani J; Michell M; Nunnerley H; Zaman S
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():151-60. PubMed ID: 2475251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.
    Onishi S; Saibara T; Fujikawa M; Sakaeda H; Matsuura Y; Matsunaga Y; Yamamoto Y
    Hepatology; 1989 Sep; 10(3):349-53. PubMed ID: 2474481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells.
    Walewski J; Paietta E; Dutcher J; Wiernik PH
    J Cancer Res Clin Oncol; 1989; 115(2):170-4. PubMed ID: 2654134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
    Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
    J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined therapy for unresectable hepatocellular carcinoma with hepatic arterial infusion of lymphokine-activated killer cells from autologous splenocytes and of lipiodolized antitumor agent].
    Chuganji Y; Matsuzaki Y; Ebihara T; Shoda J; Nishi M; Matsumoto H; Tanaka N; Koyama S; Fukutomi H; Osuga T
    Nihon Shokakibyo Gakkai Zasshi; 1990 Feb; 87(2):256-62. PubMed ID: 2157913
    [No Abstract]   [Full Text] [Related]  

  • 12. Lysis of primary hepatic tumours by lymphokine activated killer cells.
    Hsieh KH; Shu SY; Lee CS; Chu CT; Yang CS; Chang KJ
    Gut; 1987 Feb; 28(2):117-24. PubMed ID: 3030899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
    N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vivo distribution of human peripheral blood lymphocytes and lymphokine-activated killer cells adoptively transferred in human pancreatic cancer-bearing nude mice.
    Marincola FM; Drucker BJ; Keeling CA; Siao DY; Starnes HF; Goodwin DA; Holder WD
    Surgery; 1989 Jan; 105(1):79-85. PubMed ID: 2492121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers.
    Komatsu T; Yamauchi K; Furukawa T; Obata H
    J Clin Immunol; 1990 May; 10(3):167-74. PubMed ID: 2164039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional immunochemotherapy in hepatocellular carcinoma.
    Kountouras J; Boura P; Kouklakis G
    Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.